부산대학교 도서관

However, ESAs were shown in regular care not only to have a transfusion-sparing effect (and thus to reduce the transfusion burden) in lower-risk MDS patients, but also to result in greater survival if patients had not received any transfusions yet [[10]]. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Notably, lenalidomide offers patients with del 5q a relatively good prognosis of survival so that in this patient subgroup, the prognostic value of transfusion dependency might indeed be smaller, however, to verify this, a much greater patient cohort would be needed. [Extracted from the article]